The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2021 | Latest updates on treating plasma cell dyscrasias
Meral Beksac, MD, Ankara University, Ankara, Turkey, shares the latest updates on the treatment of plasma cell dyscrasias, as presented at EBMT 2021. Dr Beksac outlines the discovery and utilization of novel biomarkers, such as translocation of (11;14), as well as new data from the Phase III ANDROMEDA trial (NCT03201965) investigating daratumumab for the treatment of amyloidosis, bispecific antibody therapies, and the latest updates in chimeric antigen receptor T-cell (CAR-T) therapy. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
Disclosures
Dr Meral Beksac, MD, has participated in advisory boards or speakers bureaus with Amgen, BMS, Celgene, Janssen, Oncopeptides, Sanofi and Takeda.
